Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2285354 | 1.00 | DUT (0.37) | DUT | |
| SCHEMBL5168130 | 1.00 | DUT (0.37) | DUT | |
| SCHEMBL4778591 | 1.00 | DUT (0.37) | DUT | |
| SCHEMBL741996 | 1.00 | DUT (0.37) | DUT | |
| SCHEMBL4773208 | 1.00 | DUT (0.37) | DUT | |
| SCHEMBL2805480 | 1.00 | DUT (0.37) | DUT | |
| SCHEMBL1535294 | 1.00 | DUT (0.37) | DUT | |
| SCHEMBL5651326 | 1.00 | DUT (0.37) | DUT | |
| SCHEMBL581065 | 1.00 | DUT (0.37) | DUT | |
| SCHEMBL1535321 | 1.00 | DUT (0.37) | DUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 204 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120028191-A1 | Azide Functionalized Poly(3-Hexylthiophene) and Method of Forming Same | BROOKHAVEN SCIENCE ASSOCIATES, LLC (US) | 2012-02-02 | — | — | US | claimed |
| EP-4746969-A1 | HETEROCYCLIC PAD4 INHIBITORS | Bristol-Myers Squibb Company (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-4737504-A2 | CATIONIC LIPID, LIPOSOME CONTAINING CATIONIC LIPID, AND NUCLEIC-ACID PHARMACEUTICAL COMPOSITION CONTAINING LIPOSOME AND FORMULATION AND APPLICATION THEREOF | Xiamen Sinopeg Biotech Co., Ltd. (CN) | 2026-05-06 | — | — | EP | disclosed |
| EP-4276090-B1 | CATIONIC LIPID, LIPOSOME CONTAINING CATIONIC LIPID, AND NUCLEIC-ACID PHARMACEUTICAL COMPOSITION CONTAINING LIPOSOME AND PREPARATION AND APPLICATION THEREOF | XIAMEN SINOPEG BIOTECH CO LTD (CN) | 2026-04-29 | — | — | EP | disclosed |
| EP-4712948-A2 | GENE EDITING SYSTEMS AND COMPOSITIONS FOR TREATMENT OF HEMOGLOBINOPATHIES AND METHODS OF USING THE SAME | Renagade Therapeutics Management Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20260021046-A1 | LIPID NANOPARTICLE AND PHARMACEUTICAL COMPOSITION | UNIV HOKKAIDO NAT UNIV CORP (JP) | 2026-01-22 | — | — | US | disclosed |
| US-12492202-B2 | Macrocyclic PAD4 inhibitors useful as immunosuppressant | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-12-09 | — | — | US | disclosed |
| US-20250346554-A1 | METHOD FOR PURIFYING COMPOSITION | JSR CORPORATION (JP) | 2025-11-13 | — | — | US | disclosed |
| US-20250313525-A1 | CONSTRAINED LIPIDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MAN INC (US) | 2025-10-09 | — | — | US | disclosed |
| WO-2025134066-A1 | IONIZABLE LIPIDS | BIONTECH DELIVERY TECHNOLOGIES GMBH (DE) | 2025-06-26 | — | — | WO | disclosed |
| US-6229029-B1 | SELECTIVE ESTROGENS EFFECTING BONE, THE CARDIOVASCULAR SYSTEM AND THE CENTRAL NERVOUS SYSTEM; HORMONE REPLACEMENT THERAPY; OSTEOPOROSIS; NO ACTIVITY IN THE UTERUS AND LIVER | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-05-08 | — | — | US | disclosed |
| EP-1087959-A1 | NOVEL BENZOPYRAN OR THIOBENZOPYRAN DERIVATIVES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2001-04-04 | — | — | EP | disclosed |
| WO-1999065893-A1 | NOVEL BENZOPYRAN OR THIOBENZOPYRAN DERIVATIVES | C & C RESEARCH LABORATORIES (KR) | 1999-12-23 | — | — | WO | disclosed |
| US-5877296-A | REACTING DISULFIDE ANALOGS OF CALICHEAMICIN FAMILY WITH A CARRIER SUCH AS PROTEIN, PEPTIDE, MONO AND POLYCLONAL ANTIBODIES, THEIR ANTIGEN-RECOGNIZING FRAGMENTS AND CHEMICALLY OR GENETICALLY ENGINEERED COUNTERPARTS | AMERICAN CYANAMID COMPANY (US) | 1999-03-02 | — | — | US | disclosed |
| US-5773001-A | ANTIGROWTH AGENTS | AMERICAN CYANAMID COMPANY (US) | 1998-06-30 | — | — | US | disclosed |
| US-5767285-A | USEFUL FOR CONSTRUCTING DRUG CONJUGATES; ANTIBIOTIC ANTITUMOR AGENTS | AMERICAN CYANAMID COMPANY (US) | 1998-06-16 | — | — | US | disclosed |
| EP-0693287-A1 | RNA cleaving or binding oligonucleotides | HOECHST AKTIENGESELLSCHAFT (DE) | 1996-01-24 | — | — | EP | disclosed |
| EP-0689845-A2 | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis | AMERICAN CYANAMID COMPANY (US) | 1996-01-03 | — | — | EP | disclosed |
| EP-0625203-A1 | SYNTHETIC HAEMOPHILUS INFLUENZAE CONJUGATE VACCINE | CONNAUGHT LABORATORIES LIMITED (CA) | 1994-11-23 | — | — | EP | disclosed |
| WO-1993015205-A2 | SYNTHETIC HAEMOPHILUS INFLUENZAE CONJUGATE VACCINE | CONNAUGHT LABORATORIES LIMITED (CA) | 1993-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250313525-A1 | CONSTRAINED LIPIDS AND METHODS OF USE THEREOF | SGMS1, SGMS2, LNPEP | DUT 997/4885 |
| US-20260021046-A1 | LIPID NANOPARTICLE AND PHARMACEUTICAL COMPOSITION | FABP1, RHOA, STAT6 | DUT 3428/4885 |
| US-20250346554-A1 | METHOD FOR PURIFYING COMPOSITION | HSD17B7, AKR1C3, DEGS1 | DUT 4521/4885 |
| US-20120028191-A1 | Azide Functionalized Poly(3-Hexylthiophene) and Method of Forming Same | NUDT1, NMT1, MPST | DUT 729/4885 |
| US-12492202-B2 | Macrocyclic PAD4 inhibitors useful as immunosuppressant | PADI4, PADI1, PADI2 | DUT 750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.